Evidence map›Paper›PMID 39321191›Full record

ArticlePloS one2024

Demographic and pathogen characteristics of incident bacterial meningitis in infants in South Africa: A cohort study.

Yannick Nkiambi Kiakuvue, Sumaya Mall, Nelesh Govender, Anne von Gottberg, Rudzani Mashau, Susan Meiring, Cheryl Cohen

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yannick Nkiambi KiakuvueSchool of Public Health, Division of Epidemiology and biostatistics, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7175-6409
Sumaya MallSchool of Public Health, Division of Epidemiology and biostatistics, University of the Witwatersrand, Johannesburg, South Africa.
Nelesh GovenderSchool of Public Health, Division of Epidemiology and biostatistics, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-7869-9462
Anne von GottbergSchool of Public Health, Division of Epidemiology and biostatistics, University of the Witwatersrand, Johannesburg, South Africa.
Rudzani MashauCentre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, Johannesburg, South Africa.
Susan MeiringCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
Cheryl CohenSchool of Public Health, Division of Epidemiology and biostatistics, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-0376-2302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBacterial meningitis is a major cause of death, with an approximate case fatality rate of 37% across all age groups in South Africa. This study aimed to describe the demographic and pathogen characteristics of incident meningitis in children aged <1 year in South Africa from 2014 through 2018, during a period when Haemophilus influenzae type b vaccine and pneumococcal conjugate vaccines (PCV) were both included in the expanded program on immunization (EPI).

methodsWe conducted a cohort study of routine laboratory data in the National Health Laboratory Service Corporate Data Warehouse, which covers approximately 80% of the South African population. We defined a case of laboratory-confirmed bacterial meningitis as any person aged <1 year with meningitis diagnosed by culture and identification of a pathogen documented as being a common cause of meningitis in CSF. The cause-specific incidence risks were calculated by dividing the number of positive specimens in each age group and year by the corresponding mid-year population for children under 1 year old and those in the post-neonatal period (≥ 28 days to 365 days old). For children under 28 days old, the annual numbers of registered livebirths were used. We used Poisson regression to compare the incidence of meningitis by year.

resultsWe identified 3575 (1.5%) cases of culture-confirmed bacterial meningitis from the 232,016 cerebrospinal fluid (CSF) specimens tested from 2014-2018. The highest number of cases were recorded in children aged <28 days (1873, 52.4%), male children (1800, 50.4%) as well as in the Gauteng Province (2014, 56.3%). Acinetobacter baumannii (14.9%), followed by Klebsiella pneumoniae (13.5%), and group B streptococcus (GBS) (10.7%), were the most common pathogens detected. Overall, A. baumannii had the highest incidence risk, occurring at 9.8 per 100,000 persons in children aged <1 year in 2018. Among neonates, A. baumannii peaked at 14.9 per 100,000 livebirths in 2018, while Streptococcus pneumoniae was most common in the post-neonatal period (≥ 28 days to 365 days old), peaking at 9.8 per 100,000 persons in 2014. There was an increase in the annual incidence of most pathogens over the study period.

conclusionThere was an increasing trend in the annual incidence of bacterial meningitis in infants caused by most pathogens, particularly A. baumannii, K. pneumoniae and GBS. In addition to increased uptake of vaccination, prevention measures to reduce nosocomial and mother-to-child transmission of bacteria could include antenatal screening for GBS in pregnant women, rigorous hygiene in the hospital environment as well as rational antibiotic use.

Indexed as

Meningitis, BacterialAcinetobacter baumanniiCohort StudiesFemaleHaemophilus VaccinesHumansIncidenceInfantInfant, NewbornKlebsiella pneumoniaeMalePneumococcal VaccinesSouth AfricaStreptococcus pneumoniaeHaemophilus VaccinesPneumococcal Vaccines

Identifiers

PMID39321191
PMCPMC11423971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.